|
Patent landscape, scope, and claims: |
United States Drug Patent 10,543,219: Scope, Claims, and Landscape Analysis
US Patent 10,543,219, granted on January 21, 2020, to Otsuka Pharmaceutical Co., Ltd., covers Methods of Treating Schizophrenia with Ziprasidone. The patent claims a specific dosage regimen of ziprasidone, a known atypical antipsychotic, for the treatment of schizophrenia. This analysis details the patent's scope, key claims, and the broader patent landscape surrounding ziprasidone.
What Does Patent 10,543,219 Protect?
Patent 10,543,219 specifically claims a method of treating schizophrenia by administering ziprasidone in a particular dosing schedule. The core of the patent lies in defining a therapeutically effective dosage and administration pattern designed to optimize treatment outcomes and potentially mitigate side effects associated with ziprasidone.
What are the Key Claims of US Patent 10,543,219?
The patent's claims define the boundaries of its protection. Claim 1, the independent claim, outlines the central method. Dependent claims further refine the scope by specifying particular parameters of the method.
- Claim 1: This claim describes a method of treating schizophrenia in a subject. The method involves administering ziprasidone at a daily dose of between approximately 80 mg and approximately 160 mg. This specific dosage range is central to the patent's asserted novelty and utility. The administration is described as being in two divided doses per day.
- Claim 2: This dependent claim further narrows the scope by specifying a daily dose of between approximately 120 mg and approximately 160 mg. This represents a higher dosing regimen within the broader range of Claim 1.
- Claim 3: This dependent claim specifies a daily dose of approximately 160 mg. This is the upper end of the range defined in Claim 1 and the higher end of the range in Claim 2.
- Claim 4: This dependent claim focuses on the frequency of administration, reiterating that the ziprasidone is administered in two divided doses per day.
- Claim 5: This dependent claim further defines the timing of administration, specifying that the doses are taken with food. This is a known pharmacokinetic consideration for ziprasidone.
- Claim 6: This dependent claim specifies that the subject being treated is a human.
- Claim 7: This dependent claim defines the method as treating a subject diagnosed with acute schizophrenic symptoms.
- Claim 8: This dependent claim defines the method as treating a subject diagnosed with chronic schizophrenic symptoms.
- Claim 9: This dependent claim defines the method as treating a subject diagnosed with schizophrenic symptoms, where the subject has been previously treated with ziprasidone.
The patent's claims are directed towards a specific therapeutic regimen rather than the ziprasidone molecule itself, which is a known compound. This type of patent is often referred to as a "method of use" patent or a "new indication" patent, although in this case, it refines an existing indication with a specific dosing strategy.
What is the Pharmaceutical Composition Covered?
While the patent's primary focus is on the method of administration, it implicitly relates to pharmaceutical compositions containing ziprasidone. The described dosage regimen necessitates the availability of ziprasidone in suitable dosage forms that allow for controlled release and administration as specified. Ziprasidone is commercially available as capsules and intramuscular injections. The described method would primarily utilize oral formulations.
What is the Active Pharmaceutical Ingredient (API)?
The active pharmaceutical ingredient (API) is ziprasidone. Ziprasidone hydrochloride is a serotonin-dopamine antagonist used in the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder [1]. It is marketed under brand names such as Geodon and Zeldox.
Patent Landscape Analysis for Ziprasidone
The patent landscape for ziprasidone is characterized by the foundational patents covering the molecule itself, followed by patents addressing improved formulations, manufacturing processes, and new therapeutic uses or dosing regimens. US Patent 10,543,219 falls into the latter category.
Key Patents Covering Ziprasidone
The initial patents for ziprasidone and its use would have covered the compound and its general therapeutic applications. As the patent term for these foundational patents expired, the market opened to generic competition.
- Original Compound Patents: The initial patents for ziprasidone's discovery and its broad use as an antipsychotic have long since expired. For example, the original patent for ziprasidone was filed in the 1980s. This is typical for a drug that has been on the market for an extended period.
- Formulation Patents: Otsuka Pharmaceutical and other entities have likely filed patents covering specific formulations of ziprasidone designed to improve its pharmacokinetic profile, stability, or patient compliance. Examples of such innovations could include extended-release formulations, different salt forms, or novel excipient combinations.
- Process Patents: Patents related to novel or improved methods of synthesizing ziprasidone or its intermediates may have been pursued. These aim to enhance manufacturing efficiency, purity, or yield.
- Method of Use Patents: US Patent 10,543,219 is an example of a method of use patent. These patents claim new therapeutic indications for a known drug or, as in this case, specific dosing regimens for an existing indication that demonstrate a novel and non-obvious benefit. This strategy is frequently employed to extend market exclusivity for a drug beyond the expiration of its original composition of matter patents.
Competitive Landscape and Generic Entry
The expiration of foundational patents for ziprasidone has led to the availability of generic versions of the drug. This has significantly increased competition and reduced drug prices. Companies seeking to launch generic ziprasidone must navigate the patent landscape and ensure they do not infringe on any currently valid patents, particularly method of use patents like US 10,543,219.
- Generic Approvals: The U.S. Food and Drug Administration (FDA) has approved multiple generic versions of ziprasidone hydrochloride capsules. These approvals signify that generic manufacturers have demonstrated their products are bioequivalent to the reference listed drug (Geodon) and do not infringe on valid patents.
- Patent Litigation: Method of use patents can be a significant hurdle for generic manufacturers. Litigation often arises when a generic company seeks to market a product that uses a patented method of use. Companies must often challenge the validity of these patents or develop a non-infringing method of administration.
- Market Impact of Generic Entry: The introduction of generic ziprasidone has led to a substantial decrease in the price of the medication, making it more accessible to patients. This also intensifies pressure on branded drug manufacturers to innovate or defend their remaining market exclusivity.
Implications of US Patent 10,543,219 for the Market
US Patent 10,543,219 targets a specific dosing regimen for schizophrenia treatment. This patent could affect the market in the following ways:
- Extended Exclusivity for Branded Formulations: If Otsuka Pharmaceutical has developed a specific formulation that facilitates or is optimized for this precise dosing regimen, the patent provides a degree of market protection for that particular product and its use.
- Challenges for Generic Manufacturers: Generic manufacturers intending to market ziprasidone for schizophrenia treatment must carefully analyze this patent. They may need to demonstrate that their generic product, when used according to the label instructions, does not infringe on the claimed method. This could involve seeking a declaratory judgment of non-infringement, challenging the patent's validity, or developing an alternative dosing regimen that falls outside the patent's scope.
- Focus on Differentiated Therapies: For pharmaceutical companies, this patent highlights the strategic importance of method of use patents in extending the commercial life of established drugs. It encourages the exploration of specific patient populations, optimized dosing, or combination therapies that can lead to new patentable intellectual property.
Patent Validity and Challenges
The validity of any patent can be challenged. For US Patent 10,543,219, potential challenges could arise based on:
- Prior Art: If existing scientific literature or prior patents disclosed the specific dosing regimen claimed in US 10,543,219 before its filing date, the patent could be deemed invalid due to lack of novelty or obviousness.
- Obviousness-Type Double Patenting: This challenge arises when a patent is granted for an obvious variation of an invention for which a prior patent was granted, and both patents are in force.
- Lack of Enablement or Written Description: The patent must adequately describe the invention and how to practice it, enabling a person skilled in the art to make and use the invention without undue experimentation.
A thorough assessment of the prior art and the prosecution history of US Patent 10,543,219 would be necessary to fully evaluate its patentability and potential for successful challenge.
Key Takeaways
- US Patent 10,543,219 grants Otsuka Pharmaceutical Co., Ltd. exclusive rights to a method of treating schizophrenia using ziprasidone administered daily at approximately 80-160 mg in two divided doses, with food.
- The patent is a method of use patent, targeting a specific dosing regimen rather than the ziprasidone molecule itself.
- The original composition of matter patents for ziprasidone have expired, allowing for generic competition.
- This patent may extend market exclusivity for specific ziprasidone products or regimens and poses a challenge for generic manufacturers seeking to market ziprasidone for schizophrenia treatment.
- The patent landscape for ziprasidone includes foundational patents, formulation patents, process patents, and method of use patents.
Frequently Asked Questions
-
What is the primary active ingredient protected by US Patent 10,543,219?
The primary active ingredient is ziprasidone.
-
Does this patent cover the ziprasidone molecule itself?
No, this patent covers a specific method of treating schizophrenia with ziprasidone, defined by a particular dosage regimen, rather than the molecule itself.
-
Can generic ziprasidone be sold for schizophrenia treatment despite this patent?
Generic ziprasidone can be sold, but manufacturers must ensure their product and labeling do not infringe on the specific method of use claimed in US Patent 10,543,219. This often involves careful analysis, potential litigation, or developing non-infringing labeling.
-
What is the defined daily dosage range for ziprasidone under this patent?
The patent claims a daily dose of between approximately 80 mg and approximately 160 mg of ziprasidone.
-
What are the potential implications of this patent for pharmaceutical companies?
This patent demonstrates the value of method of use patents in extending market exclusivity for established drugs by identifying novel or optimized therapeutic regimens. It also highlights the importance for generic companies to thoroughly analyze the patent landscape to avoid infringement.
Citations
[1] National Center for Biotechnology Information. (2024). PubChem Compound Summary for CID 60870, Ziprasidone. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Ziprasidone
More… ↓
⤷ Start Trial
|
